This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

John W. Gamel, MD; Charles C. Barr, MD
Louisville, Ky

Arch Ophthalmol. 1993;111(11):1462-1463.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Based on the findings reported recently in the ARCHIVES by Berson et al,¹ the National Retinitis Pigmentosa Foundation and the RP Foundation Fighting Blindness have begun national campaigns that will probably persuade most patients with RP to begin a lifelong regimen of vitamin A supplementation. This media blitz was launched despite important and compelling uncertainties raised in an accompanying editorial by Massof and Finkelstein.² The authors of this editorial discuss at length three reservations, including the use of an electrophysiologic parameter (ERG [electroretinogram] amplitude) to measure clinical impact.

We wish to raise an additional concern. In reality, Berson et al¹ measured three variables—ERG amplitude, visual acuity, and visual fields. Had any one of these three shown a response to therapy, would they have interpreted this finding as a successful outcome? Furthermore, Berson et al measured clinical impact for two agents (vitamins A and E), and they performed . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?